Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute, St. Bortolo Hospital, Vicenza, Italy.
Blood Purif. 2013;36(1):47-51. doi: 10.1159/000350586. Epub 2013 May 25.
To improve hemodialysis (HD) patients' clinical tolerance and quality of life, a new paradigm of technological evolution of the artificial kidney needs to be addressed at this point. Compared to the second law of thermodynamics, if HD is a barrier against entropy increase, personal daily dialysis (PDD), taking account of multidimensional treatment parameters specific to the patient, can be a new treatment option. Here, we review currently used HD equipment and competing technologies of the wearable artificial kidney (WAK) for future application to PDD. Biofeedback control during HD personalizes treatment parameters such as blood volume changes, thermal energy balance and biochemical variables in well-defined ranges and tries to deliver the targeted treatment dose without intradialytic hypotension. Miniaturized devices such as WAK could also meet the needs of patients by providing mobility, the possibility of normal social activities and flexibility of treatment schedule. So far, many studies have shown the future direction of renal replacement therapy for chronic patients: personalization and daily treatment. PDD might require a new index including a biological plan for recovery of homeostasis and a strategy toward long-term rehabilitation of the patient. The concept of entropy includes these multidimensional factors, and the artificial kidney should be evolved to minimize the increase in entropy of the patient.
为了提高血液透析(HD)患者的临床耐受性和生活质量,此时需要解决人工肾技术演变的新范式。与热力学第二定律相比,如果 HD 是对抗熵增的屏障,那么考虑到患者特定的多维治疗参数的个人每日透析(PDD)可以成为一种新的治疗选择。在这里,我们回顾了目前用于 PDD 的 HD 设备和可穿戴人工肾(WAK)的竞争技术。HD 期间的生物反馈控制使治疗参数个性化,例如血液量变化、热能平衡和生化变量在明确定义的范围内,并尝试在不发生透析中低血压的情况下提供靶向治疗剂量。WAK 等小型化设备也可以通过提供移动性、正常社交活动的可能性和治疗计划的灵活性来满足患者的需求。到目前为止,许多研究都表明了慢性患者肾脏替代治疗的未来方向:个性化和每日治疗。PDD 可能需要一个新的指标,包括恢复体内平衡的生物学计划和患者长期康复的策略。熵的概念包括这些多维因素,人工肾应该进化以最小化患者熵的增加。